Clinical Trial Update: A Study to Evaluate the Effect of Gefapixant (AF-219/MK-7264) on Methacholine Hyper-reactivity in Participants With Asthma (MK-7264-009) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Gefapixant (AF-219/MK-7264) for its effect on methacholine-induced hyperreactivity in participants with asthma; study completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Gefapixant (gefapixant)

Snippet

Sponsor: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2021-02-03